We are monitoring the impact of COVID-19 on APAC Biologics Market Get in touch with us for detailed analysis Know More
Pulished Date March, 2021
ID: 11309
Share on
Share on

APAC Biologics Market Research Report – Segmented By Source, Product, Biologics Manufacturing Type, Disease Category and Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) – Industry Size, Share, Trends, Growth & Forecast (2020 to 2025)

Pulished: March, 2021
ID: 11309
Pages: 100

APAC Biologics Market Size (2020 to 2025)

The Asia-Pacific Biologics Market size is forecasted to be growing at a steady growth rate during the forecast period.

The market's growth is majorly driven by the factors such as increasing demand for innovative therapies, Y-O-Y rise in the prevalence of chronic diseases in this region, and drastic changes in people's social behavior. An increase in population and changes in social behavior are projected to propel market growth. Moreover, the biopharmaceutical contract manufacturing market is developing majorly due to the accelerating demand for biologics and growing outsourcing by the pharmaceutical companies in developing companies such as China and India in the APAC region. On the other hand, increasing capital investment from critical players and growing population is most likely to propel the market growth. Furthermore, Robust advancements in research and development activities and emerging markets are expected to increase the biologics market growth.

The APAC market is facing some growth challenges. Such as the stringent regulatory process for biologics; moreover, the biologics process requires high capital investments, which cannot be affordable in emerging countries such as India, considered the growth decline factor. The primary concern factors such as biologics drugs are highly complex and require control and maintenance throughout the development and production process; these factors are expected to restrain the market growth. In the biologics process, development and quality control procedures involve colossal capital investment at the initial state process. 

Impact of COVID-19 on the APAC Biologics market:

COVID-19 was identified in Wuhan, China. Later it transmitted throughout the world, including the Asia Pacific region. As per reports from January 3, 2020, to March 10, 2021, there have been 102,152 cases confirmed in China. The biologics market growth in Asia Pacifica had been disrupted during the pandemic lockdown, the biologics medical products and manufacturing pharmaceutical drugs had been postponed. The extraction of biologics products has not been performed due to stringent covid-19 guidelines. The supply chain was also disrupted due to the ban on transportation. Later the uplift of lockdown, many biologics safety testing has been performed by the manufacturers to detect virus, Mycoplasma, and bacterial toxins. The market has experienced a specific growth soon after the uplift of lockdown.   

This research report on the APAC Biologics Market has been segmented & sub-segmented into the following categories:

By Source:  

  • Microbial
  • Mammalian
  • Others

By Product:

 

  • Monoclonal Antibodies
  • Vaccines
  • Recombinant Proteins
  • Antisense, RNAi, & Molecular Therapy
  • Others

By Biologics Manufacturing:

  • Outsourced
  • In-house

By Disease Category:

  • Oncology
  • Infectious Diseases
  • Immunological Disorders
  • Cardiovascular Disorders
  • Hematological Disorders
  • Others

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Among these countries, China accounted for the majority market share in the APAC region in 2019, and it is estimated to continue the dominating trend during the forecast period. The Chinese biologics market size is expected to grow at a CAGR of 9.5% during the forecast period. The presence of significant biologics teams in China, which consequently produces high demand for biologics, influences the market expansion. As per the World Health Organization, it is estimated that many new cancer cases will be reported during the forecast period.

On the other hand, the Indian biologics market is one of the fastest-growing regions in the APAC biologics market. Increasing consciousness regarding health among the people in this region and rapidly growing population is boosting the biologics market.

The Biologics market in Japan has held the largest market share over the forecast period. Japan is contributing to the Asia Pacific region growth. Market growth is attributed to ceaseless expansion in the product portfolio with a growing demand for biologics and a rising prevalence of chronic diseases.

The Australian biologics market witnessed significant growth over the forecast period because of incessant investments in biologics and developments in cellular and gene therapies.

New Zealand had moderate growth in the biologics market over the forecast period, and it is expected to increase during the forecast period. The market players in New Zealand are focussing on strategic initiatives to gain significant market growth of biologics.

Companies such as Johnson & Johnson (J&J), F Hoffmann-La Roche, Bristol-Myers Squibb, GlaxoSmithKline, AbbVie, Amgen, Sanofi, Eli Lilly, and Company, Merck & Co., and Pfizer Inc. are playing a dominating role in the APAC Biologics market.

  1. Introduction
    1. Market Definition
    2. Study Deliverables
    3. Base Currency, Base Year and Forecast Periods
    4. General Study Assumptions
  2. Research Methodology
    1. Introduction
    2. Research Phases
        1. Secondary Research
        2. Primary Research
        3. Econometric Modelling
        4. Expert Validation
    3. Analysis Design
    4. Study Timeline
  3. Overview
    1. Executive Summary
    2. Key Inferences
    3. New Developments
  4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
    1. Market Drivers
    2. Market Restraints
    3. Key Challenges
    4. Current Opportunities in the Market
  5. Market Segmentation
    1. By Source
      1. Microbial
      2. Mammalian
      3. Others
    2. By Product
      1. Monoclonal Antibodies
      2. Vaccines
      3. Recombinant Proteins
      4. Antisense, RNAi, & Molecular Therapy
      5. Others
    3. By Biologics Manufacturing
      1. Outsourced
      2. In-house
    4. By Disease Category
      1. Oncology
      2. Infectious Diseases
      3. Immunological Disorders
      4. Cardiovascular Disorders
      5. Hematological Disorders
      6. Others
  6. Geographical Analysis
    1. Introduction    
      1. Regional Trends   
      2. Impact Analysis    
      3. Y-o-Y Growth Analysis        
        1. By Geographical Area
        2. By Product
        3. By Technology
        4. By Application
        5. By End-User
      4. Market Attractiveness Analysis      
        1. By Geographical Area
        2. By Product
        3. By Technology
        4. By Application
        5. By End-User
      5.      Market Share Analysis   
        1. By Geographical Area
        2. By Product
        3. By Technology
        4. By Application
        5. By End-User
    2. Asia-Pacific
      1. Introduction
      2. India
      3. China
      4. Japan
      5. South Korea
      6. Australia
  7. Strategic Analysis
    1. PESTLE analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
      5. Legal
      6. Environmental
    2. Porter’s Five analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Consumers
      3. Threat of New Entrants
      4. Threat of Substitute Products and Services
      5. Competitive Rivalry within the Industry
  8. Market Leaders' Analysis
    1. Johnson & Johnson (J&J)
      1. Overview
      2. Product Analysis
      3. Strategic Evaluation and Operations
      4. Financial analysis
      5. Legal issues
      6. Recent Developments
      7. SWOT analysis
      8. Analyst View
    2. F Hoffmann-La Roche
    3. Bristol-Myers Squibb
    4. GlaxoSmithKline
    5. AbbVie
    6. Amgen
    7. Sanofi
    8. Eli Lilly and Company
    9. Merck & Co.
    10. Pfizer
  9. Competitive Landscape
    1. Market share analysis
    2. Merger and Acquisition Analysis
    3. Agreements, Collaborations and Joint Ventures
    4. New Product Launches
  10. Market Outlook and Investment Opportunities
  11. Appendix
    1. List of Tables
    2. List of Figures  
  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail.
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development.
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment.
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies.
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions.
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market.
  1. Asia Pacific Biologics Market, By Source, From 2020 to 2025 (USD Billion)
  2. Asia Pacific Microbial Market, By Region, From 2020 to 2025 (USD Billion)
  3. Asia Pacific Mammalian Market, By Region, From 2020 to 2025 (USD Billion)
  4. Asia Pacific Others Market, By Region, From 2020 to 2025 (USD Billion)
  5. Asia Pacific Biologics Market, By Product, From 2020 to 2025 (USD Billion)
  6. Asia Pacific Monoclonal Antibodies Market, By Region, From 2020 to 2025 (USD Billion)
  7. Asia Pacific Vaccines Market, By Region, From 2020 to 2025 (USD Billion)
  8. Asia Pacific Recombinant Proteins Market, By Region, From 2020 to 2025 (USD Billion)
  9. Asia Pacific Antisense, RNAi, & Molecular Therapy Market, By Region, From 2020 to 2025 (USD Billion)
  10. Asia Pacific Others Market, By Region, From 2020 to 2025 (USD Billion)
  11. Asia Pacific Biologics Market, By Biologics Manufacturing, From 2020 to 2025 (USD Billion)
  12. Asia Pacific Outsourced Market, By Region, From 2020 to 2025 (USD Billion)
  13. Asia Pacific In-house Market, By Region, From 2020 to 2025 (USD Billion)
  14. Asia Pacific Biologics Market, By Disease Category, From 2020 to 2025 (USD Billion)
  15. Asia Pacific Oncology Market, By Region, From 2020 to 2025 (USD Billion)
  16. Asia Pacific Infectious Diseases Market, By Region, From 2020 to 2025 (USD Billion)
  17. Asia Pacific Immunological Disorders Market, By Region, From 2020 to 2025 (USD Billion)
  18. Asia Pacific Cardiovascular Disorders Market, By Region, From 2020 to 2025 (USD Billion)
  19. Asia Pacific Hematological Disorders Market, By Region, From 2020 to 2025 (USD Billion)
  20. Asia Pacific Others Market, By Region, From 2020 to 2025 (USD Billion)
  21. Japan Biologics Market, By Source, From 2020 to 2025 (USD Billion)
  22. Japan Biologics Market, By Product, From 2020 to 2025 (USD Billion)
  23. Japan Biologics Market, By Biologics Manufacturing, From 2020 to 2025 (USD Billion)
  24. Japan Biologics Market, By Disease Category, From 2020 to 2025 (USD Billion)
  25. China Biologics Market, By Source, From 2020 to 2025 (USD Billion)
  26. China Biologics Market, By Product, From 2020 to 2025 (USD Billion)
  27. China Biologics Market, By Biologics Manufacturing, From 2020 to 2025 (USD Billion)
  28. China Biologics Market, By Disease Category, From 2020 to 2025 (USD Billion)
  29. India Biologics Market, By Source, From 2020 to 2025 (USD Billion)
  30. India Biologics Market, By Product, From 2020 to 2025 (USD Billion)
  31. India Biologics Market, By Biologics Manufacturing, From 2020 to 2025 (USD Billion)
  32. India Biologics Market, By Disease Category, From 2020 to 2025 (USD Billion)
  33. Australia Biologics Market, By Source, From 2020 to 2025 (USD Billion)
  34. Australia Biologics Market, By Product, From 2020 to 2025 (USD Billion)
  35. Australia Biologics Market, By Biologics Manufacturing, From 2020 to 2025 (USD Billion)
  36. Australia Biologics Market, By Disease Category, From 2020 to 2025 (USD Billion)
  37. South Korea Biologics Market, By Source, From 2020 to 2025 (USD Billion)
  38. South Korea Biologics Market, By Product, From 2020 to 2025 (USD Billion)
  39. South Korea Biologics Market, By Biologics Manufacturing, From 2020 to 2025 (USD Billion)
  40. South Korea Biologics Market, By Disease Category, From 2020 to 2025 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample